Caution Regarding Forward-Looking Information
In addition to historical information, this Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of benefiting
All statements contained in this Form 10-Q, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words "believe," "expect," "anticipate," "intends," "estimate," "forecast," "project," and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future revenue, economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under Item 1A - Risk Factors beginning on page 21 below that may cause actual results to differ materially. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company's views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Significant Accounting Policies and Estimates
The discussion and analysis of the Company's financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, management evaluates past judgments and estimates, including those related to bad debts, inventories, accrued liabilities, derivative liabilities and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies and related risks described in the Company's annual report on Form 10-K as filed with the
SECon September 27, 2021are those that depend most heavily on these judgments and estimates. As of March 31, 2022, there had been no material changes to any of the critical accounting policies contained therein. Overview Isorayis a brachytherapy device manufacturer with FDA clearance for a single medical device that can be delivered to the physician in multiple configurations as prescribed for the treatment of cancers in multiple body sites. The Company manufactures and sells this product as the Cesium-131 brachytherapy seed or Cesium Blu. The brachytherapy seed utilizes Cesium-131, with a 9.7 day half-life, as its radiation source. The Company believes that it is the unique combination of the short half-life and the energy of the Cesium-131 isotope that are yielding the beneficial treatment results that have been published in peer reviewed journal articles and presented in various forms at conferences and tradeshows. The Company has distribution agreements outside of the United States. These distributors are responsible for obtaining regulatory clearance to sell the Company's products in their territories, with the support of the Company. As of the date of this Report, the Company has distributors in the Russian Federation, Peruand Indiawith no reported revenues in these locations during the three months ended March 31, 2022. The Company has a supply agreement with The Open Joint Stock Company< > ("JSC Isotope"), a Russian company, for the supply of Cesium-131 for a term of August 2020to December 2021. On March 18, 2021, the Company entered into a new supply contract (the "New Agreement") with JSC Isotope pursuant to which the Company will purchase Cesium-131 for a term from March 18, 2021through March 31, 2023. Our source of supply of Cesium-131 from Russiais historically produced using one of two nuclear reactors which supply the irradiation needed for Cesium-131 production. As a result of scheduled shutdowns in 2021 and prior years, only one of the Company's historic Russian suppliers of Cesium-131 was available during these periods.
The Company has entered into two consignment inventory agreements with
(“Medikor”) to process the Company’s enriched barium in one of the reactors mentioned above. The duration of the first enriched barium consignment agreement began in
September 9, 2021, the Company entered into a second Consignment Agreement with Medikor. Pursuant to this second Consignment Agreement, the Company purchased 6,000 mg of enriched barium carbonate for $720,000and consigned this inventory to Medikor. Beginning in October 2021, Medikor started to use the barium carbonate consigned by the Company (along with barium carbonate consigned under the original agreement) and contract with a third-party manufacturer to produce Cesium-131. Pursuant to this second Consignment Agreement, Medikor pays the Company varying US dollar amounts per curie of Cesium-131 the Company purchases. The amount varies based on how many curies of Cesium-131 the Company purchases. The consignment agreements are expected to minimize the impact on the Company of the temporary shutdown of one of the nuclear reactors that serves as its source of Cesium-131 from Russia. The Company's affiliate Medical also has a services agreement with Medikor originally entered into in August 2017in conjunction with the first consignment agreement, which was superseded by a new services agreement dated December 13, 2021, to perform qualitative and quantitative chemical analysis of Cesium-131 through December 31, 2022. On March 31, 2022, the Company entered into two agreements with Medikor to purchase enriched barium carbonate. Under the first agreement, the Company purchased 5746.6 mg of enriched barium carbonate for $876,357. Under the second agreement, the Company purchased 6310.4 mg of enriched barium carbonate for $957,608. The Company expects to receive delivery of the enriched barium carbonate by June 30, 2022. The Company estimates that this enriched barium will result in approximately 6,000 curies of Cesium-131. There is no assurance as to whether the Company will obtain this full amount of Cesium-131, nor is there assurance that the third-party reactor which relies on this enriched barium will be used by the Cesium-131 supplier under contract with the Company. The Company continues to explore how our proprietary isotope may be effective in the treatment of additional cancers. We recently entered into a research grant agreement with a leading cancer center to study the treatment of metastatic melanoma. In this immuno-oncology study, Cesium-131 will be used in combination with an immune checkpoint inhibitor. Metastatic melanoma is the most virulent form of skin cancer, often spreading to lymph nodes, the lungs, liver, brain, and tissue under the skin. We also have an agreement with the University of Cincinnatito study the combination of Cesium-131 with the immunotherapy drug Keytruda® in recurrent head and neck cancers. The Company recently filed a nonprovisional patent application for a device designed to achieve directional dosing using our Cesium-131 seeds. This device is a bed that holds the Cesium-131 seeds to focus the radiation to a specific treatment area. The device is fixed to a directional mesh that can be used to treat pancreatic cancers as well as retroperitoneal sarcomas. We see unidirectional brachytherapy utilizing Cesium-131 as a highly attractive potential therapy for advanced abdominal cancers as well. In this practical application, the device will be aimed at cancers of the abdomen that invade the abdominal wall and pelvic floor, such as advanced cancers of the colon and rectum and advanced GYN cancers such as ovarian and uterine cancers. The directional dosing device will likely be used initially with the recurrent cancers mentioned above where our competitors' external beam radiation therapy has previously been administered. Results of Operations
Three months completed
Three months ended March 31, 2022 2021 2022 - 2021 Amount % (a) Amount % (a) % Change Sales, net $ 2,910 100
$ 2,600100 12 Cost of sales 1,469 50 1,238 48 19 Gross profit 1,441 50 1,362 52 6 Operating expenses: Research and development expenses 549 19 362 14 52 Sales and marketing expenses 687 24 581 22 18 General and administrative expenses 1,581 54 1,183 46 34 Loss on equipment disposal - - 2
- (100 ) Total operating expenses 2,817 97 2,128 82 32 Operating loss $ (1,376 ) (47 )
$ (766 )(29 ) 80
(a) Expressed as a percentage of sales, net
End of nine months
Nine months ended March 31, 2022 2021 2022 - 2021 Amount % (a) Amount % (a) % Change Sales, net
$ 8,290100 $ 7,343100 13 Cost of sales 4,600 55 3,568 49 29 Gross profit 3,690 45 3,775 51 (2 ) Operating expenses: Research and development expenses 1,786 22 959 13 86 Sales and marketing expenses 2,150 26 1,781 24 21 General and administrative expenses 5,039 61 3,379 46 49 Loss on equipment disposal - - 9 - (100 ) Total operating expenses 8,975 109 6,128 83 46 Operating loss $ (5,285 )(64 ) $ (2,353 )(32 ) 125 (a) Expressed as a percentage of sales, net 14
Table of Contents Sales Sales, net for the three and nine months ended
March 31, 2022increased 12% and 13% respectively compared to the three and nine months ended March 31, 2021. The Company's sales personnel continue to focus on bringing in new accounts while also working with existing customers to increase their order volumes. Hospitals' focus on COVID-19 during the three months ended March 31, 2022has waned slightly in some areas but has continued in other areas and this has continued to impact patients' brachytherapy procedures. Further, we believe that hospitals are continuing to have a difficult time staffing nurses needed to support the procedures our products are utilized in.
The breakdown of sales between prostate and non-prostate applications is shown below.
Three months completed
Three months ended March 31, 2022 2021 2022 - 2021 Amount % (a) Amount % (a) % Change Prostate brachytherapy
$ 2,18775 $ 2,03378 8 Other sales 723 25 567 22 28 Sales, net $ 2,910100 2,600 100 12 (a) Expressed as a percentage of sales, net
End of nine months
Nine months ended March 31, 2022 2021 2022 - 2021 Amount % (a) Amount % (a) % Change
8 Other sales 1,991 24 1,525 21 31 Sales, net
$ 8,290100 7,343 100 13 (a) Expressed as a percentage of sales, net 15
Table of Contents Prostate Brachytherapy Prostate sales increased by approximately 8% during the three and nine months ended
March 31, 2022compared to the three and nine months ended March 31, 2021. We believe that due to hospitals' focus on COVID-19 including the Delta and Omicron variants during the nine months ended March 31, 2022in various states, patients' brachytherapy procedures continued to be delayed or cancelled. Despite these delays and cancellations, revenues increased over the prior year three months mainly due to a price increase instituted by the Company along with slightly higher number of cases, and revenues increased over the prior year nine months due to a combination of an increased number of seeds being sold and a price increase instituted by the Company. The sales volume increase was primarily related to increased utilization at existing accounts as well as sales to new accounts. The Company raised seed prices in November 2021to help offset its increases in raw materials and other costs as a result of the ongoing global COVID-19 pandemic. Management believes continued growth in prostate brachytherapy revenues will be the result of physicians, payors, and patients increasingly considering overall treatment advantages including costs compared with non-brachytherapy treatments, better treatment outcomes and improvement in the quality of life for patients. In January 2022, the American Cancer Societyestimated that nearly 270,000 new prostate cancer cases will be diagnosed in calendar year 2022, which represents an increase of approximately 8% over the calendar year 2021 estimate ( American Cancer Society, 2022). This increase is due to patients being unable to access treatment or putting treatment off due to the COVID pandemic, but there is no assurance that this will occur and if it occurs that it will have a positive impact on the Company's performance. We believe the trend to use brachytherapy in lieu of other options is starting to improve our performance but there is no assurance as to how long this trend will continue. Other Sales Other sales includes, but is not limited to, brain, lung, head/neck, gynecological, and pelvis treatments, as well as services. Other sales, net increased by 28% for the three months ended March 31, 2022and 31% for the nine months ended March 31, 2022compared to the three and nine months ended March 31, 2021. The main driver of this growth was treatments for pelvic and brain cancers as well as increased services. The increase in services was mainly due to an increase in the minimum order fee due from GT Medical Technologies as its forecast was greater than its actual orders during the three and nine months ended March 31, 2022. Initial applications for these other brachytherapy treatments are primarily used in recurrent cancer treatments or salvage cases that are generally difficult to treat aggressive cancers where other treatment options are either ineffective or unavailable. Other brachytherapy treatments are subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of physicians. This causes the revenue created by these types of treatment applications to be more volatile and varies significantly from year to year. Individual centers weigh the value of the procedure with their other treatment priorities on a patient by patient basis. Other brachytherapy treatments, such as brain, lung, and head/neck are typically performed in the in-patient setting using the DRG or diagnostic related groups. DRGs are designed for Medicare to set payment levels for hospital in-patient services. Other health insurers may follow Medicare reimbursement when setting their payment rates. When these other types of brachytherapy are performed in the out-patient setting, existing codes for Cesium-131 that are also used for prostate brachytherapy are used to bill for these procedures. GammaTile™ For several years the Company has focused on many different applications of its Cesium-131 brachytherapy seeds in the cranial cavity to target many forms of brain cancer. Most recently, the Company has focused on using braided strand configurations and supplying Cesium-131 brachytherapy seeds to GT Medical Technologies, Inc.("GT Med Tech") which manufactures GammaTile™ Therapy. On November 17, 2021, Medical entered into Amendment No. 3 to its Amended and Restated Manufacturing and Supply Agreement with GT Med Tech to change the nature of the services provided by Medical from preparation of GammaTiles™ containing Cesium-131 seeds to instead only supplying Cesium-131 seeds to GT Med Tech so that GT Med Tech may handle the assembly of GammaTiles™ in house. GammaTile™ Therapy uses biodegradable "tiles" to deliver Cesium-131 brachytherapy seeds into contact with cancerous tumors in the brain. GammaTile™ Therapy was originally cleared for treating recurrent brain cancers. GT Med Tech filed a 510k with the FDA on an expanded indication of GammaTile™ Therapy to include treatment of newly diagnosed brain tumors with an application of Cesium-131. On January 27, 2020, GT Med Tech announced that it had received clearance from the FDA for an expanded indication allowing patients of newly diagnosed malignant brain tumors to be treated by GammaTile™ Therapy. For the three and nine months ended March 31, 2022, total revenues from sales including minimum order fees to GT Med Tech were approximately 13% and 13% of sales respectively. Cost of sales Cost of sales consists primarily of the costs of manufacturing and distributing the Company's products and for the three and nine months ended March 31, 2022increased 19% and 29% respectively compared to the three and nine months ended March 31, 2021. Contributing to the increase in the three and nine months ended March 31, 2022and 2021 comparison were increases in isotope and other materials costs as well as increases in labor and depreciation. Due to lower than forecasted levels of sales volumes, we had excess isotope on hand which went unused. Other materials costs increased due to supplier price increases. Labor costs increased due to annual merit increases for production personnel as well as additional headcount and depreciation increased due to completion of production automation projects and the purchase of other production equipment. 16
Table of Contents Gross Profit Contributing to the three months ended
March 31, 2022versus three months ended March 31, 2021gross profit increase were higher sales offset by increased costs of production including isotope supply due to ordering additional supply and payroll due to merit increases. Contributing to the nine months ended March 31, 2022versus the nine months ended March 31, 2021gross profit decline were increases in isotope costs due to lower than forecasted sales volumes which led to excess isotope on hand which went unused along with ordering additional isotope as part of the initial setup of a second reactor, and increases in payroll due to annual merit increases and additional headcount. Additionally, material costs increased compared to the three and nine months ended March 31, 2021. Research and development
Research and development primarily includes employee and third party costs related to research and development activities.
Contributing to the three and nine months ended
March 31, 2022and 2021 comparison was an increase in payroll due to annual merit increase as well as additional headcount and an increase in consulting expenses relating to market research. This increase was partially offset by a reduction in investment in the development of the Blu Build™ delivery system for real-time prostate brachytherapy. On December 31, 2020, the Company received FDA 510k clearance for use of C4 Imaging's Sirius® positive-signal MRI (Magnetic Resonance Imaging) markers with the Company's Cesium-131 brachytherapy seeds. Sirius® is implanted during the treatment of prostate cancer with the Cesium-131 seeds and is used to facilitate seed localization within the prostate utilizing a single post-implant MRI procedure. We finished our premarket activities related to the Sirius® marker during the first quarter of fiscal 2022 and we started a product performance evaluation (formerly referred to as a limited market release) on this technology in the second quarter of fiscal 2022 and expect it to be available for full market release later in fiscal year 2022 but there is no assurance this timing will occur.
Management expects research and development spending to remain at this level as we continue to explore new projects and collaborations.
Sales and marketing expenses
Selling and marketing expenses consist primarily of costs related to the internal and external activities of the Company’s sales, marketing and customer service functions. We plan to increase the number of Territory Managers from 7 to 10 over the next 12 months, but there is no guarantee that this will happen.
Contributing to the three and nine months ended
March 31, 2022and 2021 comparison was an increase in travel and tradeshow costs due to some COVID-19 restrictions being eased as well as increased payroll expenses resulting from annual merit increases, new hires and an increase in incentive compensation due to the increase in sales. These increases were partially offset by a reduction in consulting expenses due to reclassification of reimbursement consulting to general and administrative expenses.
General and administrative expenses
General and administrative expenses consist primarily of the costs related to the executive, human resources/training, quality assurance/regulatory affairs, finance, and information technology functions of the Company. Contributing to the three and nine months ended
March 31, 2022and 2021 comparison were increased payroll due to annual merit increases and new hires, employment hiring expenses, IT consulting expenses, director and officer insurance expense, public company related expenses, increased audit and legal fees, severance, and increased travel due to the easing of some COVID-19 restrictions. In addition, the majority of annual employee and director stock grants have historically been granted in the fiscal fourth quarter, however awards for performance in fiscal 2021 were granted in July 2021thereby increasing share-based stock compensation expense in the nine months ended March 31, 2022compared to the nine months ended March 31, 2021. 17
Impact of conflict in
In February of 2022,
Russiainvaded Ukraineand is still engaged in active armed conflict against the country. As a result, governments in the United States, the European Union, the United Kingdom, Switzerland, and other countries have enacted sanctions against Russiaand Russian interests, and in turn Russiahas implemented some retaliatory sanctions and currency controls as well. These sanctions include controls on the export, re-export, and in-country transfer in Russiaof certain goods, supplies, and technologies and the imposition of restrictions on doing business with certain state-owned Russian customers and other investments and business activities in Russia. Certain Russian banks have been impacted as well through restrictions on money transfers. Our local bank implemented its own policies which ultimately resulted in our inability to make wire transfers to Russiaand we are in the process of establishing other banking relationships so that we can continue to make these wire transfers for our supply of isotope. Because of the armed conflict, we have also adjusted the transportation of our medical isotope from Russiadue to the cancellation of many flights in and out of Russia. To date, the Company has not experienced any missed shipments of medical isotope. The Company retained legal counsel to assist in its review of our medical isotope and other Russian suppliers to ensure none of them have been sanctioned, including the Russian banks that our suppliers use. Currently there are no sanctions on our suppliers nor their banks, but there can be no assurance this will not change in the future. We continue to monitor the situation. Impact of COVID-19 From the onset of the COVID-19 global pandemic we have been proactive in implementing plans to ensure the health and well-being of our employees, while remaining focused on providing uninterrupted product flow to the physicians and patients who count on us. We transitioned many employees to work from home and made other adjustments to ensure the continuity of our business through this time. At the beginning of the pandemic, we moved quickly to ensure that our inventory of non-isotope supplies were appropriate in case our supply chain was disrupted. In addition, we set in motion a strategy to maintain a continuous and uninterrupted supply of isotope from our suppliers in Russiaincluding the review and use of alternative freight services due to the cancellation of many international flights. As COVID-19 spread, many states implemented new guidelines in an attempt to mitigate the spread of the virus and to conserve certain medical supplies. Those guidelines led to the cancellation or postponement of elective and non-emergency surgical procedures, including prostate brachytherapy procedures. Although during the first nine months of fiscal 2022, our sales revenues increased 13% compared to the first nine months of fiscal 2021, we were still below the average monthly prostate revenues attained in our third quarter of fiscal 2020 prior to the outset of COVID-19's impact on our operations. We believe this is due to hospitals' focus on COVID-19 including variants, resulting in a delay or cancellation of patients scheduled to be seen by physicians. In addition, we believe that hospitals are having a difficult time staffing nurses needed to support the procedures our products are utilized in. This resulted in fewer or delayed urology referrals for prostate brachytherapy treatment. In the first nine months of fiscal 2022, we forecasted an increase in cases, particularly prostate cases, which did not occur to the extent we expected due to an increase in the Delta and Omicron variants of COVID-19 as well as increased physician vacations and staffing shortages in hospitals. We plan to continue to manage our expenses and make adjustments to isotope orders, as permitted by our suppliers, to meet potential increased treatment demands.
Cash and capital resources
The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has historically financed its operations through selling equity to investors. During the nine months ended
March 31, 2022and 2021, the Company used existing cash reserves to fund its operations and capital expenditures (in thousands except current ratio): Nine months ended March 31, 2022 2021 Net cash (used) by operating activities $ (4,819 ) $ (1,719 )Net cash (used) by investing activities (161 ) (272 ) Net cash provided by financing activities 56
Net increase (decrease) in cash and cash equivalents
$ (4,924 ) $ 62,450As of March 31, 2022 June 30, 2021 Working capital $ 60,802 $ 65,501Current ratio 32.08 37.37 18
Cash flow from operating activities
Net cash used by operating activities in the nine months ended
March 31, 2022was primarily due to a net loss of approximately $5.19 millionnet of approximately $1,171,000in adjustments for non-cash activity such as share-based compensation, depreciation and amortization expense, and accretion of asset retirement obligation. Changes in operating assets and liabilities contributed approximately $796,000to the cash used by operating activities; increases in inventory, mainly due to the purchase of enriched barium carbonate, increase in accounts receivable, and increases in prepaid expenses and other current assets were partially offset by increases in accrued payroll and related taxes, increases in accounts payable and accrued expenses, and accrued protocol expenses. Net cash used by operating activities in the nine months ended March 31, 2021was primarily due to a net loss of approximately $2.33 millionnet of approximately $428,000in adjustments for non-cash activity such as share-based compensation, depreciation and amortization expense, accretion of asset retirement obligation, and loss on equipment disposal. Changes in operating assets and liabilities provided approximately $179,000from operating activities; increases in accounts payable, accrued protocol expense, accrued vacation, and accrued radioactive waste disposal, and decreases in accounts receivable due to increased collection efforts and decreased sales, were partially offset by increases in inventory and prepaid expenses and other current assets, and a decrease in accrued payroll and related taxes.
Cash flow from investing activities
Investing activities for the nine months ended
March 31, 2022and 2021 respectively, consisted of transactions related to the purchase of fixed assets. Management will continue to invest in technology and machinery that improves and streamlines production processes and to invest in low-risk investment opportunities that safeguard assets and provide greater assurance those resources will be liquid and available for business needs as they arise.
Cash flows from financing activities
Financing activities in the nine months ended
March 31, 2022included proceeds of approximately $56,000pursuant to the exercise of options to purchase common stock. Financing activities in the nine months ended March 31, 2021, included payment of preferred dividends and net proceeds of approximately $56,375,000from the sale of 59,669,230 shares of common stock pursuant to two underwritten offerings. Also included are net proceeds of approximately $7,784,000pursuant to exercise of the 12,318,877 warrants to purchase common stock as well as net proceeds of approximately $291,000pursuant to the exercise of 520,315 options to purchase common stock.
Liquidity and capital resources projected for the financial year 2022
Operating activities Management forecasts that fiscal 2022 cash requirements will increase compared to previous years and that current cash and cash equivalents will be sufficient to meet projected operating cash needs for the next twelve months. Monthly operating expenses are budgeted to increase for sales and marketing, research and development and general and administrative expenses in fiscal 2022 as management works to implement its strategy. Assuming no extraordinary expenses occur (whether operating or capital), if management is successful at implementing its strategy to focus on renewed emphasis to drive the consumer to the prostate market and meets or exceeds its growth targets of twenty-five percent increase in revenue in fiscal 2022 and this annual growth continues, the Company anticipates reaching cashflow break-even in three to four years. These assumptions do assume that GammaTile™ will contribute to total revenue but do not incorporate any significant growth in the other non-prostate applications as they generate nominal revenues today but if they show significant improvement, cashflow break-even could occur sooner. There is no assurance that the targeted sales growth will materialize but management is encouraged by the depth and experience of its sales team and its track record of growth during the last three fiscal years despite the ongoing COVID-19 pandemic. The Company missed its target of twenty-five percent increased revenue in the first nine months of fiscal 2022 and there is no assurance that targeted sales growth will continue over the next three to four years. Capital expenditures Management has completed the design of a future production and administration facility but has not determined when or if it will move ahead with construction. If financing is obtained and the facility constructed, it is believed that the new facility will have non-cash depreciation cost equal to or greater than the monthly rental cost of the current facility. The Company has limited additional space at this time and may need more office space in the future. Management is reviewing all aspects of production operations (including process automation), research and development, sales and marketing, and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems, and personnel are available to support and drive sales. 19
Table of Contents Financing activities When it does require capital in the future, the Company expects to finance its future cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing stockholders, management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to stockholders.
Other commitments and contingencies
The Company presented its other commitments and contingencies in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2021. There have been no material changes outside of the ordinary course of business in those obligations during the nine months ended March 31, 2022other than those previously disclosed in note 7 of the financial statements contained in this filing.
Off-balance sheet arrangements
The Company has no off-balance sheet arrangements.
Significant Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and on various other factors the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results could therefore differ materially from those estimates if actual conditions differ from our assumptions. During the nine months ended
March 31, 2022, there have been no changes to the critical accounting policies and estimates discussed in Part II, Item 7 of our Form 10-K for the year ended June 30, 2021.
© Edgar Online, source